Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 31.45% is 104% above its 5-year average of -790.23%, near the high end of its 5-year range (-33612.67%–41.36%).
109.67% above its 12-month average of -325.12%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -737.78%.
EBITDA MARGIN
31.45%
EBITDA MARGIN AVG TTM
-325.12%
EBITDA MARGIN AVG 3Y
-278.37%
EBITDA MARGIN AVG 5Y
-790.23%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+109.67%
CURRENT VS 3Y AVG
+111.30%
CURRENT VS 5Y AVG
+103.98%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Atara Biotherapeutics, Inc.
Market Cap
$84.70M
EBITDA Margin
31.45%
TTM Avg
-325.12%
3Y Avg
-278.37%
5Y Avg
-790.23%
Market Cap
$84.75M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$84.00M
EBITDA Margin
-4911.29%
TTM Avg
-4911.29%
3Y Avg
-4895.51%
5Y Avg
-4835.22%
Market Cap
$83.96M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$87.86M
EBITDA Margin
-8103.88%
TTM Avg
-7583.93%
3Y Avg
-8667.05%
5Y Avg
-7944.60%
Market Cap
$88.21M
EBITDA Margin
15.84%
TTM Avg
9.89%
3Y Avg
0.86%
5Y Avg
4.00%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | $84.70M | 31.45% | -325.12% | -278.37% | -790.23% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $84.75M | N/A | N/A | N/A | N/A |
| Humacyte, Inc. (HUMA)vs › | $84.00M | -4911.29% | -4911.29% | -4895.51% | -4835.22% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $83.96M | N/A | N/A | N/A | N/A |
| Conexeu Sciences Inc. (CNXU)vs › | $83.49M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $86.69M | 23.63% | 23.21% | 8.97% | 9.09% |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | -8103.88% | -7583.93% | -8667.05% | -7944.60% |
| Citius Oncology, Inc. (CTOR)vs › | $81.22M | N/A | N/A | N/A | N/A |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 15.84% | 9.89% | 0.86% | 4.00% |
| electroCore, Inc. (ECOR)vs › | $91.33M | -35.83% | -39.56% | -111.97% | -250.85% |
Gross Margin
82.4%
EBITDA Margin
31.4%
Operating Margin
29.7%
Net Margin
-269.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -737.78% |
| 2026-03-31 | -647.29% |
| 2025-12-31 | -157.62% |
| 2025-09-30 | -102.46% |
| 2025-06-30 | 19.53% |
| 2025-03-31 | 41.36% |
| 2024-12-31 | -33.90% |
| 2024-09-30 | -51.07% |
| 2024-06-30 | -59.01% |
| 2024-03-31 | -109.13% |
| 2023-12-31 | -1224.65% |
| 2023-09-30 | -3199.39% |
| 2023-06-30 | -7336.78% |
| 2023-03-31 | -6019.90% |
| 2022-12-31 | -33612.67% |
| 2022-09-30 | -1867.08% |
| 2022-06-30 | -59.51% |
| 2022-03-31 | -1184.43% |
| 2021-12-31 | -1205.34% |
| 2021-09-30 | -1536.22% |
| 2021-06-30 | -2110.13% |
| 2021-03-31 | -2139.70% |
